Navigation Links
Silence Therapeutics Signs siRNA Delivery Collaboration With Top 10 Pharma Company
Date:9/26/2011

LONDON, September 27, 2011 /PRNewswire/ --

Silence Therapeutics plc (AIM: SLN) ("Silence"), a leading RNA interference (RNAi) therapeutics company, today announces that it has entered into an agreement with one of the world's leading global pharmaceutical companies to investigate the application of Silence's proprietary DACC delivery technology for intravenous delivery of short interfering RNA sequences ("siRNAs") to the pulmonary vascular endothelium.

Under the terms of the agreement, Silence's partner will provide Silence with specific siRNAs, which Silence will formulate with its DACC delivery system. Silence and its partner will undertake in vitro and in vivo studies of the DACC formulated siRNAs developed under the agreement and select lead candidates for further evaluation. Financial terms were not disclosed.

DACC is a novel lipid delivery system that includes Silence's proprietary lipid AtuFect and is used to embed siRNAs into a multiple lipid bi-layer structure. Whilst closely related to the AtuPLEX™ delivery system used in Atu027, Silence's lead oncology candidate in Phase I trials, DACC has significantly different properties on a physiochemical and pharmacological level. The DACC delivery system is incorporated in Atu111, Silence's preclinical development candidate for the treatment of acute lung injury, and enables functional, highly specific and efficient delivery of RNAi therapeutics to the pulmonary vascular endothelium. In preclinical models, the DACC delivery system has demonstrated highly focused delivery to lung tissue and sustained knockdown of the desired target gene expression in this particular cell type. Of note, the DACC delivery sys
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Silence Therapeutics Announces Issuance of Japanese Patent for Screening Therapeutics Against Key Pathway Associated with Cancer and Other Diseases
2. Silence Therapeutics and InteRNA Technologies Sign Collaboration to Develop Novel microRNA Therapeutics
3. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
4. Silence Therapeutics Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting
5. Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials
6. Silence Therapeutics Provides Year-end Update
7. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
8. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
9. Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
10. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
11. Silence Therapeutics Announces Board Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015 Pulse Light ... a survey to Rosacea sufferers as part of their ongoing ... Rosacea sufferers found effective for their Rosacea. The survey participants ... comprised 47% men and 53% women. The results ... participants did not consider or attempt to visit their GP ...
(Date:6/30/2015)... , June 30, 2015  Ardelyx, Inc. (NASDAQ: ... cardio-renal, gastrointestinal and metabolic diseases, today announced that the ... 14, 2015, from 8:00 a.m.- 1:00 pm EDT in ... The Ardelyx senior management team will present an ... compound, tenapanor, which has completed Phase 2b clinical trials ...
(Date:6/30/2015)... , BERKELEY, Kalifornien, und KOPENHAGEN, Dänemark, ... Biologics, Inc. , ein Weltmarktführer der klinischen ... anderen therapeutischen Proteinen, gab heute bekannt, dass ... der Produktionskapazität den Ausbau der nordamerikanischen Produktionsanlage ... mit der Ergänzung  einer Einweg-Anlage Bioreactor 6Pack™ ...
Breaking Medicine Technology:84% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 284% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 3Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 3
... Mass., Oct. 26, 2011 Idenix Pharmaceuticals, Inc. (NASDAQ: ... financial results for the third quarter of 2011 on Wednesday, ... Idenix management will host a conference call at 4:30 p.m. ... financial results for the third quarter of 2011 and provide ...
... MECHANICSBURG, Pa., Oct. 26, 2011 One out of three ... according to an Opinion Research/Select Medical telephone poll. Against that ... a statement today reminding the American public that influenza season ... chronic lung disease such as asthma or COPD (Chronic Obstructive ...
Cached Medicine Technology:Idenix to Host Conference Call Discussing Third Quarter and Nine Month 2011 Financial Results and Announces Presentations at the American Association for the Study of Liver Diseases Meeting (AASLD) 2Poll: One Out of Three U.S. Adults Not Planning to Get Flu Shot This Year 2
(Date:6/30/2015)... ... June 30, 2015 , ... ... Rehab”. The video focuses on the rehab center’s patients and their experiences at ... the best quality of services available. Each patient attests to the high rating, ...
(Date:6/30/2015)... ... June 30, 2015 , ... Broadway by the Sea posted its ... and family member testimonials. Medicare rated the care center as a five-star location based ... video to give future patients a firsthand look at the facility’s satisfied residents. ...
(Date:6/30/2015)... ... June 30, 2015 , ... The progress of ... multidistrict litigation now underway in the U.S. District Court, Eastern District of Louisiana, ... to the Court’s calendar, that conference has now been scheduled for July 9th, ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... community. , Eleven physicians from Allied’s Fullerton division volunteered to help provide free ... Super Surgery Saturday, March 21, at St. Jude Medical Center. , The ...
(Date:6/30/2015)... ... June 30, 2015 , ... Red Hot & Blue Restaurants, ... online poll at http://scoutology.com/novaburgerwars and was selected as “Best BBQ” in a ... 2015. , Red Hot & Blue President Randy McCann said, “Everyone knows Red Hot ...
Breaking Medicine News(10 mins):Health News:Patients of University Post-Acute Rehab Support Five-Star Rating in New Video 2Health News:Broadway by the Sea Video Promotes Top Quality Service 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 3Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 2Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 3Health News:Red Hot & Blue BBQ Restaurants Voted "Best Burger" in Virginia and "Best Barbecue" in Texas 2Health News:Red Hot & Blue BBQ Restaurants Voted "Best Burger" in Virginia and "Best Barbecue" in Texas 3
... Nov. 6, 2008 Advanced age and race are ... dies or suffers a stroke after carotid-artery surgery, a ... found. , "This study identified 11 readily available, ... surgeons and anesthesiologists better weigh the risks and benefits ...
... The Content of His Character ... Statement of Lorraine Cole, Ph.D., YWCA ... ... had the privilege of,conducting an oral history interview with Dr. Dorothy Height, who ... her move to New York to take that position, she served as the,Executive ...
... Percent Increase in IVUS System Sales, SAN DIEGO, ... a leader in the development, manufacturing and sales of,products ... artery,disease, today reported that revenues for the third quarter ... quarter of 2007., For the quarter ended September ...
... Share of $0.32 and Contract Value of $230.6 million; Announces New Program ... ... Board Company,(Nasdaq: ABCO ) today announced financial results for the second quarter ... $57.6 million, from $54.0 million in the second quarter of fiscal 2008.,Net income ...
... Ind., Nov. 5 Conseco, Inc. (NYSE:,CNO) today ... "We are pleased,with the performance of our core ... "with income before net realized investment losses,corporate interest ... the,favorable end of the estimated ranges we provided ...
... Nov. 5 The American Dental,Association (ADA) continues to ... the 2008 Golden Apple Awards. The Golden Apple,Awards program, ... society activities and excellence in leadership., The 2008 ... of the,year to the following societies:, -- ...
Cached Medicine News:Health News:Age, race are among factors that influence carotid-surgery success 2Health News:YWCA USA Recognizes Historic Election Milestone 2Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 2Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 3Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 4Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 5Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 6Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 7Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 8Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 9Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 10Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 11Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 12Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 13Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 14Health News:The Advisory Board Company Reports Fiscal Year 2009 Second Quarter Results 2Health News:The Advisory Board Company Reports Fiscal Year 2009 Second Quarter Results 3Health News:The Advisory Board Company Reports Fiscal Year 2009 Second Quarter Results 4Health News:The Advisory Board Company Reports Fiscal Year 2009 Second Quarter Results 5Health News:The Advisory Board Company Reports Fiscal Year 2009 Second Quarter Results 6Health News:The Advisory Board Company Reports Fiscal Year 2009 Second Quarter Results 7Health News:The Advisory Board Company Reports Fiscal Year 2009 Second Quarter Results 8Health News:The Advisory Board Company Reports Fiscal Year 2009 Second Quarter Results 9Health News:The Advisory Board Company Reports Fiscal Year 2009 Second Quarter Results 10Health News:Conseco Reports Third Quarter Results 2Health News:Conseco Reports Third Quarter Results 3Health News:Conseco Reports Third Quarter Results 4Health News:Conseco Reports Third Quarter Results 5Health News:Conseco Reports Third Quarter Results 6Health News:Conseco Reports Third Quarter Results 7Health News:Conseco Reports Third Quarter Results 8Health News:Conseco Reports Third Quarter Results 9Health News:Conseco Reports Third Quarter Results 10Health News:Conseco Reports Third Quarter Results 11Health News:Conseco Reports Third Quarter Results 12
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: